THE FACT ABOUT NEW ADVANCEMENTS IN BRD4 INHIBITION THERAPY ABBV-744 THAT NO ONE IS SUGGESTING

In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment till disease progression or perhaps the participants are unable to tolerate the study drugs.- Participant consumed grapefruit or grapefruit items within three days before the very fir